Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

Abstract Background Ixekizumab, an anti‐ IL ‐17A monoclonal antibody, demonstrated a high level of efficacy in moderate‐to‐severe plaque psoriasis ( PP ) patients. Objective To evaluate the efficacy and safety of open‐label ixekizumab in Japanese patients with moderate‐to‐severe PP , erythrodermic psoriasis ( EP ) and generalized pustular psoriasis ( GPP ). Methods Patients received 160‐mg subcutaneous ixekizumab injection at Week 0, 80‐mg every 2 weeks through Week 12 and 80‐mg every 4 weeks through Week 24. Efficacy and safety are reported through 24 weeks; additional safety data are available for some patients. Results A total of 78 patients with PP , 8 with EP and 5 with GPP enrolled. In PP patients, PASI 75 and PASI 90 response rates were 98.7% (77/78) and 83.3% (65/78) at Week 12 respectively. In EP patients, PASI 75 and PASI 90 were 100.0% (8/8) and 62.5% (5/8) and in GPP patients were 80.0% (4/5) and 60.0% (3/5). Overall, 84.0% (76/91) had a treatment‐emergent AE through ≥24 weeks. There were no serious AE s, deaths, cases of tuberculosis or invasive fungal infections. Limitations No control group and small sample sizes, especially for EP and GPP . Conclusion By Week 12, nearly all patients with PP , EP and GPP achieved PASI 75. The safety profile was consistent with reported results and no unexpected safety signals were observed.